Compare VanEck Junior Gold Miners (GDXJ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Zoetis Inc — how do they compare? VanEck Junior Gold Miners trades at $114.32 (market cap $8.22B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.7× VanEck Junior Gold Miners's market cap, and Zoetis Inc pays a 2.9% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Zoetis Inc for 70 Days on average.
| GDXJ | ZTS | |
|---|---|---|
Market Cap | $8.22B | $30.20B |
Volume | 3,212,198 | 6,175,327 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $147.53 |
52-Week Low | $87.56 | $69.09 |
Typical Hold Time | 41 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
